Chief Executive Officer, Nuvalent
Appears in 1 story
Selling Nuvalent to GSK
GSK closed its $10.6 billion purchase of Nuvalent in September, netting out to about $9.4 billion in cash. Both lung cancer drugs central to the deal were still under FDA review at closing; a ruling on neladalkib is due November 27.
Updated Oct 8
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
